Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea
· Delayed Price · Currency is KRW 107,400
+700 (0.66%)
Apr 29, 2026, 3:30 PM KST
Kolon TissueGene Revenue
In the year 2025, Kolon TissueGene had annual revenue of 5.16B KRW with 1.68% growth. Kolon TissueGene had revenue of 860.82M in the quarter ending December 31, 2025, with 10.50% growth.
Revenue
5.16B
Revenue Growth
+1.68%
P/S Ratio
1,752.64
Revenue / Employee
177.89M
Employees
29
Market Cap
9,041.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.16B | 85.27M | 1.68% |
| Dec 31, 2024 | 5.07B | 1.37B | 36.90% |
| Dec 31, 2023 | 3.71B | -5.75B | -60.81% |
| Dec 31, 2022 | 9.46B | 5.45B | 136.22% |
| Dec 31, 2021 | 4.00B | 447.31M | 12.58% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HLB Co., Ltd. | 84.17B |
| SK Biopharmaceuticals | 706.74B |
| LigaChem Biosciences | 141.55B |
| Peptron | 5.63B |
| Voronoi | 7.51B |
| Samsung Epis Holdings | 1,510.14B |
| OliX Pharmaceuticals | 14.67B |
| ALTEOGEN | 215.86B |